Background
Methods
Study cohort and population of interest
Exposure definition and covariates
Outcome
Statistical analyses
Results
Characteristics of the patient population
Incident MI during follow-up |
P value | |||
---|---|---|---|---|
All observations | No | Yes | ||
Total episodes, n
|
29,298
|
27,754
|
1544
| |
Age (years), mean (SD) | 76.6 (7.4) |
76.5 (7.4)
|
78.1 (7.6)
|
<0.0001
|
Gender, n (%) | 0.57 | |||
Male | 14,502 (49.5) | 13,727 (49.5) | 775 (50.2) | |
Female | 14,796 (50.5) | 14,027 (50.5) | 769 (49.8) | |
Race/ethnicity, n (%) | 0.43 | |||
White | 23,131 (79.0) | 21,922 (79.0) | 1209 (78.3) | |
Black | 3583 (12.2) | 3,374 (12.2) | 209 (13.5) | |
Hispanic | 613 (2.1) | 578 (2.1) | 35 (2.3) | |
Asian | 1,281 (4.4) | 1,224 (4.4) | 57 (3.7) | |
Native American | 100 (0.3) | 93 (0.3) | 7 (0.5) | |
Other/unknown | 590 (2.0) | 563 (2.0) | 27 (1.7) | |
Region, n (%) |
<0.0001
| |||
Northeast | 4736 (16.2) | 4428 (16.0) | 308 (20.0) | |
Midwest | 7409 (25.3) | 7003 (25.2) | 406 (26.3) | |
South | 11,797 (40.3) | 11,220 (40.4) | 577 (37.4) | |
West | 5356 (18.3) | 5103 (18.4) | 253 (16.4) | |
Charlson-Romano comorbidity Index Score, mean (SD) | 3.65 (3.23) |
3.59 (3.21)
|
4.79 (3.41)
|
<0.0001
|
Person-days of follow-up | MI cases | MI incidence rate per 1,000,000 person-days | |
---|---|---|---|
Allopurinol use | |||
Yes | 12,877,451 | 937 | 73 |
No | 8,327,742 | 607 | 73 |
Allopurinol use duration | |||
0 days | 8,327,742 | 607 | 73 |
1–180 days | 5,902,851 | 514 | 87 |
181 days to 2 years | 5,127,382 | 326 | 64 |
>2 years | 1,847,218 | 97 | 53 |
Allopurinol use, allopurinol duration, and the risk of myocardial infarction
No MI | MI |
P value | ||
---|---|---|---|---|
Not on allopurinol | On allopurinol | |||
Number of episodes | 27,754 | 607 | 937 | |
Age (years), mean (SD) | 76.5 (7.4) |
77.6 (7.5)
|
78.4 (7.6)
|
0.046
|
Gender | 0.13 | |||
Male | 13,727 (49.5) | 290 (47.8) | 485 (51.8) | |
Female | 14,027 (50.5) | 317 (52.2) | 452 (48.2) | |
Race | 0.07 | |||
White | 21,922 (79.0) | 459 (75.6) | 750 (80.0) | |
Black | 3374 (12.2) | 97 (16.0) | 112 (12.0) | |
Others | 2458 (8.8) | 51 (8.4) | 75 (8.0) | |
Charlson-Romano comorbidity index score, mean (SD) | 3.65 (3.23) |
4.52 (3.32)
|
4.96 (3.47)
|
0.01
|
Comorbidity | ||||
Diabetes | 11076 (39.91) | 290 (47.8) | 482 (51.4) | 0.16 |
Hypertension | 23456 (84.5) | 544 (89.6) | 811 (89.6) | 0.07 |
CVD | 3442 (12.4) | 106 (17.5) | 184 (19.6) | 0.28 |
PVD | 4631 (16.7) |
133 (21.9)
|
247 (26.4)
|
0.047
|
Univariate | Multivariable-adjusted (model 1)** | Multivariable-adjusted (model 2)** | ||||
---|---|---|---|---|---|---|
HR (95 % CI) |
P value | HR (95 % CI) |
P value | HR (95 % CI) |
P value | |
Age (in years) | ||||||
65 to <75 | Ref | Ref | Ref | |||
75 to <85 |
1.45 (1.29,1.62)
|
<0.0001
|
1.36 (1.21, 1.52)
|
<0.0001
|
1.36 (1.21, 1.52)
|
<0.0001
|
≥85 |
2.08 (1.81, 2.38)
|
<0.0001
|
1.92 (1.67, 2.21)
|
<0.0001
|
1.92 (1.67, 2.21)
|
<0.0001
|
Gender | ||||||
Male | Ref | Ref | Ref | |||
Female | 0.96 (0.87, 1.06) | 0.46 |
0.87 (0.79, 0.96)
|
0.007
|
0.87 (0.79, 0.96)
|
0.007
|
Race | ||||||
White | Ref | Ref | Ref | |||
Black |
1.18 (1.02, 1.37)
|
0.02
| 1.14 (0.98, 1.32) | 0.09 | 1.13 (0.97, 1.31) | 0.11 |
Other | 0.93 (0.78, 1.12) | 0.45 | 0.93 (0.77, 1.11) | 0.41 | 0.92 (0.77, 1.11) | 0.37 |
Charlson- Romano index score |
1.15 (1.14, 1.17)
|
<0.0001
|
1.15 (1.13, 1.16)
|
<0.0001
|
1.15 (1.13, 1.16)
|
<0.0001
|
Statins | 0.86 (0.66, 1.11) | 0.23 | 0.85 (0.66, 1.11) | 0.23 | 0.85 (0.65, 1.11) | 0.22 |
Beta blockers | 1.05 (0.82, 1.33) | 0.72 | 1.02 (0.79, 1.31) | 0.90 | 1.01 (0.79, 1.31) | 0.91 |
Diuretics | 0.92 (0.73, 1.17) | 0.51 | 0.84 (0.66, 1.08) | 0.18 | 0.84 (0.66, 1.08) | 0.17 |
ACE inhibitors |
1.33 (1.03, 1.70)
|
0.03
|
1.51 (1.17, 1.95)
|
0.002
|
1.51 (1.16, 1.95)
|
0.002
|
Allopurinol use |
0.88 (0.79, 0.99)
|
0.02
|
0.85 (0.77, 0.95)
|
0.004
| - | - |
Allopurinol use duration | ||||||
0 days | Ref | - | - | Ref | ||
1–180 days | 1.00 (0.86, 1.16) | 0.99 | - | - | 0.98 (0.84, 1.14) | 0.76 |
181 days to 2 years | 0.87 (0.76, 1.01) | 0.06 | - | - |
0.83 (0.72, 0.95)
|
0.009
|
>2 years |
0.71 (0.56, 0.89)
|
0.003
| - | - |
0.70 (0.56, 0.88)
|
0.002
|
Univariate | Multivariable-adjusted (model 3)** | Multivariable-adjusted (model 4)** | ||||
---|---|---|---|---|---|---|
HR (95 % CI) |
P value | HR (95 % CI) |
P value | HR (95 % CI) |
P value | |
Age (in years) | ||||||
65 to <75 | Ref | Ref | Ref | |||
75 to <85 |
1.46 (1.29, 1.65)
|
<0.0001
|
1.37 (1.21, 1.55)
|
<0.0001
|
1.37 (1.21, 1.55)
|
<0.0001
|
≥85 |
2.04 (1.76, 2.36)
|
<0.0001
|
1.88 (1.62, 2.19)
|
<0.0001
|
1.88 (1.62, 2.19)
|
<0.0001
|
Gender | ||||||
Male | Ref | Ref | Ref | |||
Female | 0.98 (0.88, 1.10) | 0.77 |
0.88 (0.79, 0.99)
|
0.03
|
0.88 (0.79, 0.99)
|
0.03
|
Race | ||||||
White | Ref | Ref | Ref | |||
Black |
1.22 (1.05, 1.43)
|
0.01
| 1.16 (0.10, 1.36) | 0.06 | 1.16 (0.99, 1.35) | 0.07 |
Other | 0.84 (0.70, 1.06) | 0.16 | 0.86 (0.70, 1.05) | 0.14 | 0.85 (0.69, 1.05) | 0.12 |
Charlson- Romano index score |
1.15 (1.14, 1.1.7)
|
<0.0001
|
1.15 (1.13, 1.16)
|
<0.0001
|
1.15 (1.13, 1.16)
|
<0.0001
|
Statins | 0.87(0.65, 1.15) | 0.31 | 0.84 (0.63, 1.13) | 0.25 | 0.84 (0.63, 1.12) | 0.24 |
Beta blockers | 1.06 (0.81, 1.38) | 0.68 | 1.01 (0.76, 1.34) | 0.96 | 1.01 (0.76,1.34) | 0.97 |
Diuretics | 1.00 (0.77, 1.30) | 0.99 | 0.91 (0.70, 1.20) | 0.50 | 0.91 (0.69, 1.19) | 0.49 |
ACE inhibitors |
1.43 (1.09, 1.88)
|
0.01
|
1.61 (1.22, 2.13)
|
0.0008
|
1.61 (1.22, 2.12)
|
0.009
|
Allopurinol use |
0.84 (0.74, 0.94)
|
0.003
|
0.81 (0.72, 0.91)
|
0.0004
| - | - |
Allopurinol use duration | ||||||
0 days | Ref | - | - | Ref | ||
1–180 days | 0.94 (0.80, 1.11) | 0.47 | 0.92 (0.78, 1.09) | 0.33 | ||
181 days to 2 years |
0.83 (0.72, 0.97)
|
0.01
|
0.79 (0.68, 0.92)
|
0.002
| ||
> 2 years |
0.68 (0.54, 0.86)
|
0.001
|
0.68 (0.53, 0.85)
|
0.001
|